In accordance with Article 9 of Regulation (EC) No 851/2004 of the European Parliament and of the Council [Regulation (EC) No 851/2004 of the European Parliament and of the Council of 21 April 2004 establishing a European Centre for disease prevention and control (OJ L 142, 30.4.2004, p. 1, ELI: http://data.europa.eu/eli/reg/2004/851/oj).], the European Centre for Disease Prevention and Control has provided, at the Commission's request, scientific assistance on the establishment of case definitions for antimicrobial consumption, arenavirus infection, Crimean-Congo haemorrhagic fever, filovirus infection, Hantavirus infection, healthcare-associated COVID-19, Lyssavirus infection, mpox, respiratory viral infections (influenza-like illness, acute respiratory infection, severe acute respiratory infection, COVID-19, seasonal influenza, zoonotic influenza, and RSV infection), Rift Valley fever. The assistance also included the revision of the case definitions for botulism, chikungunya virus disease, chlamydial infection including chlamydial lymphogranuloma venerum, cholera, variant Creutzfeldt-Jakob disease, dengue, gonococcal infection, hepatitis B, hepatitis C, Legionnaires’ disease, malaria, measles, plague, Q fever, rubella, Shiga toxin-producing E. coli infection, shigellosis, smallpox, syphilis and congenital syphilis, tick-borne encephalitis, tuberculosis, tularaemia, West Nile virus infection, intestinal yersiniosis, Zika virus disease, antimicrobial resistance and healthcare-associated infections. The respective case definitions should be amended accordingly.
Recital 12, Regulation (EU) 2026/2097
In forcesince 18 Sep 2026